Prague Med. Rep. 2024, 125, 187-194
https://doi.org/10.14712/23362936.2024.18
Pharmacokinetic-based Dosing Individualization of Mycophenolate Mofetil in Solid Organ Transplanted Patients
References
1. 2015) Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert Opin. Drug Metab. Toxicol. 11, 921–936.
< , L. M., Riva, N., de Winter, B. C., Hesselink, D. A., de Wildt, S. N., Cransberg, K., van Gelder, T. (https://doi.org/10.1517/17425255.2015.1033397>
2. 2020) Mycophenolic acid and its pharmacokinetic drug-drug interactions in humans: Review of the evidence and clinical implications. J. Clin. Pharmacol. 60, 295–311.
< , J., Pruksakorn, D., Koonrungsesomboon, N. (https://doi.org/10.1002/jcph.1565>
3. 2021) Personalized therapy for mycophenolate: Consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther. Drug Monit. 43, 150–200.
< , S., Brunet, M., Hesselink, D. A., Johnson-Davis, K. L., Kunicki, P. K., Lemaitre, F., Marquet, P., Molinaro, M., Noceti, O., Pattanaik, S., Pawinski, T., Seger, C., Shipkova, M., Swen, J. J., van Gelder, T., Venkataramanan, R., Wieland, E., Woillard, J. B., Zwart, T. C., Barten, M. J., Budde, K., Dieterlen, M. T., Elens, L., Haufroid, V., Masuda, S., Millan, O., Mizuno, T., Moes, D., Oellerich, M., Picard, N., Salzmann, L., Tonshoff, B., van Schaik, R. H. N., Vethe, N. T., Vinks, A. A., Wallemacq, P., Asberg, A., Langman, L. J. (https://doi.org/10.1097/FTD.0000000000000871>
4. 1996) Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br. J. Clin. Pharmacol. 41, 513–516.
< , R., Shah, J., Goldblum, R., Schiff, M. (https://doi.org/10.1046/j.1365-2125.1996.03636.x>
5. 1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. 34, 429–455.
< , R. E., Nicholls, A. J., Kamm, B. R. (https://doi.org/10.2165/00003088-199834060-00002>
6. 2002) Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 62, 1060–1067.
< , D., Perico, N., Gaspari, F., Gotti, E., Remuzzi, G. (https://doi.org/10.1046/j.1523-1755.2002.00531.x>
7. 2018) Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant. Ren. Fail. 40, 395–402.
< , H. S., Demir, E., Karadeniz, M. S., Tefik, T., Nane, I., Oguz, F. S., Aydin, F., Turkmen, A. (https://doi.org/10.1080/0886022X.2018.1489285>
8. 2011) Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: Implications for therapeutic drug monitoring. Clin. J. Am. Soc. Nephrol. 6, 656–663.
< , B. C., Mathot, R. A., Sombogaard, F., Vulto, A. G., van Gelder, T. (https://doi.org/10.2215/CJN.05440610>
9. 2017) Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin. Pharmacol. Drug Dev. 6, 76–85.
< , A. H., Desai, A., Han, D., Howieson, C., Kato, K., Akhtar, S., Kowalski, D., Lademacher, C., Lewis, W., Pearlman, H., Mandarino, D., Yamazaki, T., Townsend, R. (https://doi.org/10.1002/cpdd.284>
10. 2005) Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am. J. Transplant. 5, 987–994.
< , D. A., van Hest, R. M., Mathot, R. A., Bonthuis, F., Weimar, W., de Bruin, R. W., van Gelder, T. (https://doi.org/10.1046/j.1600-6143.2005.00779.x>
11. 2014) Pharmacogenetics and immunosuppressive drugs. Expert Rev. Clin. Pharmacol. 7, 821–835.
< , K., Sima, M., Svetlik, S., Matouskova, O., Slanar, O. (https://doi.org/10.1586/17512433.2014.966811>
12. 2007) Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J. Clin. Pharmacol. 47, 6–12.
< , P., Green, K., Rogosheske, J., Brunstein, C., Ebeling, B., DeFor, T., McGlave, P., Weisdorf, D. (https://doi.org/10.1177/0091270006295064>
13. 2007) Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. Liver Transpl. 13, 791–796.
< , A., Venkataramanan, R., Kwong, T., Mohanka, R., Orloff, M., Abt, P., Kashyap, R., Tsoulfas, G., Mack, C., Williamson, M., Batzold, P., Bozorgzadeh, A. (https://doi.org/10.1002/lt.21146>
14. 2009) Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: Part II. Clin. Pharmacokinet. 48, 489–516.
< , C., Marquet, P. (https://doi.org/10.2165/11317240-000000000-00000>
15. 2000) Impairment of mycophenolate mofetil absorption by iron ion. Clin. Pharmacol. Ther. 68, 613–616.
< , M., Ueno, K., Ogawa, A., Kato, R., Yoshimura, H., Wada, K., Hashimoto, H., Takada, M., Tanaka, K., Nakatani, T., Shibakawa, M. (https://doi.org/10.1067/mcp.2000.111480>
16. 2006) Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients. Clin. Pharmacol. Ther. 80, 509–521.
< , M., Kuypers, D. R., Streit, F., Armstrong, V. W., Oellerich, M., Verbeke, K., Vanrenterghem, Y. (https://doi.org/10.1016/j.clpt.2006.08.002>
17. 2004) The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol. Dial. Transplant. 19, 2630–2633.
< , A. K., Buhle, F., Bauer, S., Mai, I., Budde, K., Haffner, D., Neumayer, H. H., Querfeld, U. (https://doi.org/10.1093/ndt/gfh446>
18. 2015) No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: A randomized crossover study. Br. J. Clin. Pharmacol. 80, 1086–1096.
< , O., Glander, P., Hambach, P., Mai, M., Brakemeier, S., Klonower, D., Halleck, F., Singer, E., Schrezenmeier, E. V., Durr, M., Neumayer, H. H., Budde, K. (https://doi.org/10.1111/bcp.12664>
19. 2001) The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. Liver Transpl. 7, 739–742.
< , L. E., Rasmussen, A., Norrelykke, M. R., Poulsen, H. E., Hansen, B. A. (https://doi.org/10.1053/jlts.2001.26365>
20. 2019) Therapeutic drug monitoring of antibiotic agents: Evaluation of predictive performance. Eur. J. Hosp. Pharm. 26, 85–88.
< , M., Bakhouche, H., Hartinger, J., Cikankova, T., Slanar, O. (https://doi.org/10.1136/ejhpharm-2017-001396>
21. 2014) Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. Ther. Drug Monit. 36, 148–151.
< , L., Clark Ojo, T., Park, J. M., Annesley, T., Bartos, C., Cibrik, D. M. (https://doi.org/10.1097/FTD.0b013e3182a8eea9>
22. 2017) The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. Br. J. Clin. Pharmacol. 83, 812–822.
< , J. T., de Winter, B. C., Hesselink, D. A., Sombogaard, F., Wang, L. L., van Gelder, T. (https://doi.org/10.1111/bcp.13154>
23. 2008) Pharmacokinetics of mycophenolic acid and its phenolic-glucuronide and ACYl glucuronide metabolites in stable thoracic transplant recipients. Ther. Drug Monit. 30, 282–291.
< , L. S., Partovi, N., Levy, R. D., Riggs, K. W., Ensom, M. H. (https://doi.org/10.1097/FTD.0b013e318166eba0>
24. 2000) Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. Eur. J. Clin. Pharmacol. 56, 659–664.
< , M., Pietrabissa, A., Mosca, F., Pacifici, G. M. (https://doi.org/10.1007/s002280000227>
25. 2002) Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm. Res. 19, 921–925.
< , L. X., Amidon, G. L., Polli, J. E., Zhao, H., Mehta, M. U., Conner, D. P., Shah, V. P., Lesko, L. J., Chen, M. L., Lee, V. H., Hussain, A. S. (https://doi.org/10.1023/A:1016473601633>
26. 2017) Clinical pharmacokinetics of mycophenolic acid in hematopoietic stem cell transplantation recipients. Eur. J. Drug Metab. Pharmacokinet. 42, 183–189.
< , D., Chow, D. S. (https://doi.org/10.1007/s13318-016-0378-6>
27. 2010) Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J. Clin. Pharmacol. 50, 1280–1291.
< , W., Fakhoury, M., Deschenes, G., Roussey, G., Brochard, K., Niaudet, P., Tsimaratos, M., Andre, J. L., Cloarec, S., Cochat, P., Bensman, A., Azougagh, S., Jacqz-Aigrain, E. (https://doi.org/10.1177/0091270009357429>